Spinal cord infarction is extremely uncommon among vascular events, accounting for only 0.3-1% of all strokes and 5-8% of acute myelopathies. While deep vein thrombosis, pulmonary embolism, and stroke are commonly observed complications of COVID-19, spinal cord infarction is relatively rare.

The COVID-19 pandemic caused by the SARS-CoV-2 virus continues to impact populations worldwide, emphasizing the need for improved diagnostic and treatment strategies. Understanding the immune response and identifying early diagnostic markers are crucial in this endeavor. In this comprehensive commentary, we delve into a recent study that investigated the immune cell profiles and NLRP3 gene expression as potential diagnostic markers in COVID-19 patients. 

Spinal dural arteriovenous fistulae (sdAVFs) are rare (5-10 per million per year), often misdiagnosed vascular lesions most commonly found in the thoracolumbar spine [1-7]. These lesions commonly present with progressive myelopathy in male (approximately 80%) patients who are usually in their 7th decade of life [3-6,8]. 

Pancreatic ductal adenocarcinoma (PAC) is an aggressive malignancy that is frequently locally invasive or widely metastatic at the time of diagnosis. As such, morbidity and mortality remain extremely high. Despite growing advances in surgical technique and medical management, the incidence and mortality rate are expected to increase over the next two decades. 

Sézary's Syndrome consists of a rare type of non-Hodgkin cutaneous T-cell lymphoma (CTCL), being a very aggressive leukemic variant of CTCL. Given its rarity and its ability to mimic other more common diseases, this neoplasm represents a major diagnostic challenge for both clinicians and pathologists.